Optimal timing to discontinue ticagrelor before cardiac surgery: do we need additional evidence?

Eur J Cardiothorac Surg. 2019 Apr 1;55(4):720-721. doi: 10.1093/ejcts/ezy420.

Authors

Mate Petricevic¹, Anders Jeppsson², Philippe Kolh³

Affiliations

¹ Department of Cardiac Surgery, School of Medicine University of Zagreb, University Hospital Center Zagreb-Rebro, Zagreb, Croatia.
² Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
³ Department of Biomedical and Preclinical Sciences, University of Liège, Liège, Belgium.

PMID: 30715309
DOI: 10.1093/ejcts/ezy420

No abstract available

Keywords: Dual antiplatelet therapy; Personalized medicine; Platelet function; Ticagrelor.

Publication types

Comment

MeSH terms

Cardiac Surgical Procedures*
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Ticagrelor*

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Ticagrelor